Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fortress Biotech (FBIO) EBIT Margin (2016 - 2025)

Fortress Biotech (FBIO) has 12 years of EBIT Margin data on record, last reported at 39.01% in Q3 2025.

  • For Q3 2025, EBIT Margin rose 11202.0% year-over-year to 39.01%; the TTM value through Sep 2025 reached 1604.66%, up 233821.0%, while the annual FY2024 figure was 7358.6%, 463644.0% down from the prior year.
  • EBIT Margin reached 39.01% in Q3 2025 per FBIO's latest filing, up from 222.22% in the prior quarter.
  • Across five years, EBIT Margin topped out at 58.11% in Q4 2024 and bottomed at 8826.0% in Q2 2022.
  • Average EBIT Margin over 5 years is 661.67%, with a median of 236.77% recorded in 2021.
  • Peak YoY movement for EBIT Margin: tumbled -858581bps in 2022, then soared 853780bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 339.25% in 2021, then grew by 2bps to 333.05% in 2022, then skyrocketed by 115bps to 49.2% in 2023, then increased by 18bps to 58.11% in 2024, then plummeted by -167bps to 39.01% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 39.01% in Q3 2025, 222.22% in Q2 2025, and 169.85% in Q1 2025.